Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Synopsys, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.25 (market cap $2.81B), while Synopsys, Inc. trades at $462.84 (market cap $91.97B). The key difference: Synopsys, Inc. is far larger — about 32.7× Dyne Therapeutics Inc. Common Stock's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Synopsys, Inc. for 72 Days on average.
| DYN | SNPS | |
|---|---|---|
Market Cap | $2.81B | $91.97B |
Volume | 2,195,902 | 3,203,530 |
Sector | Health | Technology |
52-Week High | $26.78 | $534.56 |
52-Week Low | $14.60 | $367.70 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $2.13B | $99.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Synopsys (SNPS) trades at $494.51, down 1.59% on the day, but maintains a bullish technical outlook with strong support near $493. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $3.91 exceeding expectations. Recent news highlights partnerships with OpenAI and Amazon, fueling investor optimism and driving a 13% stock surge on October 1, 2026. Valuation ratios remain elevated, with a P/E of 83.76, reflecting high growth expectations.
The outlook for SNPS is positive, supported by AI-driven demand and strategic acquisitions, but risks include high valuation and integration challenges from the Ansys deal. Analyst consensus is strongly bullish with a $575.93 price target, indicating ~16% upside. Investors should weigh growth potential against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
